Add BrightSurf on Google Email

Prescribe fewer antidepressants, and for shorter periods, doctors advised

A review suggests that doctors should prescribe fewer antidepressants and for shorter periods due to the potential severity and duration of withdrawal symptoms. The use of antidepressants is also associated with a range of side effects, but clinical trial data often don't assess outcomes that matter most to patients.

SourceBMJ Group·JournalDrug and Therapeutics Bulletin·TypeCommentary/editorial·DateDec 20, 2021

COVID patients on SSRI antidepressants are less likely to die, UCSF-Stanford study finds

A large US-based analysis of electronic health records found that people taking SSRI antidepressants, particularly fluoxetine, were significantly less likely to die from COVID-19. The results add to evidence suggesting SSRIs may have beneficial effects against the worst symptoms of COVID-19.

SourceUniversity of California - San Francisco·JournalJAMA Network Open·TypeComputational simulation/modeling·DateNov 15, 2021

Ketamine rapidly improves cognitive function making those in suicidal crisis less likely to harm themselves

A five-year study from Columbia University found that a single dose of ketamine improved thinking and reasoning, independent of depressive symptoms, making those in suicidal crisis less likely to harm themselves. The study also showed greater cognitive improvements in those given ketamine compared to midazolam.

SourceColumbia University Irving Medical Center·JournalJournal of Clinical Psychiatry·TypeObservational study·DateNov 4, 2021

Staying on long-term antidepressants reduces risk of relapse

A new study by UCL researchers has found that staying on long-term antidepressants reduces the risk of relapse by 39% compared to those who stop taking them. The study involved 478 primary care patients and found that 56% experienced a relapse within a year if they discontinued their medication, while only 26% did so after a full year.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 29, 2021

Antidepressants inhibit cancer growth in mice

Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.

SourceUniversity of Zurich·JournalScience Translational Medicine·DateSep 28, 2021

Study finds long-term injectable medications combined with counseling improves adherence and symptoms in patients with bipolar disorder

Researchers from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine found that combining long-term injectable medications with psychosocial intervention improves adherence and symptoms in patients with bipolar disorder. The study enrolled 30 people with bipolar disorder who had adherenc...

SourceUniversity Hospitals Cleveland Medical Center·JournalThe Primary Care Companion to The Journal of Clinical Psychiatry·TypeExperimental study·DateSep 16, 2021

Antidepressants safe during pregnancy

A recent study found that mothers with psychiatric disorders had a higher risk of autism spectrum disorder (ASD) and developmental delay in their children. In contrast, antidepressant use was not associated with an increased risk of ASD. The research provides reassurance for pregnant women taking SSRIs.

SourceElsevier·JournalBiological Psychiatry·DateJun 24, 2021

Lower and safer doses of laughing gas relieve treatment-resistant depression in phase 2 trial

A phase 2 trial found that a single one-hour treatment with nitrous oxide can relieve symptoms of treatment-resistant depression for several weeks. The study showed significant improvements in depression symptoms, with a four-fold lower risk of adverse effects at lower concentrations.

SourceAmerican Association for the Advancement of Science (AAAS)·JournalScience Translational Medicine·DateJun 9, 2021

Magic mushroom compound performs at least as well as leading antidepressant in small study

In a small study, psilocybin, the active compound in magic mushrooms, was found to be at least as effective as a leading antidepressant medication in reducing depressive symptoms. The results showed that depression scores decreased more quickly and were greater in magnitude in the psilocybin group compared to the escitalopram group.

SourceImperial College London·JournalNew England Journal of Medicine·DateApr 14, 2021

Psychedelic experience may not be required for psilocybin's antidepressant-like benefits

Researchers found that psilocybin restored the pleasure response in mice with depression, even when the psychedelic effects were blocked. The study suggests that a version of the drug without or with less psychedelic effects could be developed to make therapy more accessible and cost-effective.

SourceUniversity of Maryland School of Medicine·JournalProceedings of the National Academy of Sciences·DateApr 13, 2021

Geisel study examines variation in intensity of fracture-associated prescription drug use

A new Geisel-led study found substantial regional variation in the intensity of fracture-associated drug (FAD) use among long-term care facility residents, with areas experiencing higher FAD use having higher hip fracture rates. The study analyzed Medicare data and prescription records, revealing a 12% difference in FAD prescribing ran...

SourceThe Geisel School of Medicine at Dartmouth·JournalJournal of General Internal Medicine·DateFeb 16, 2021